View Author
patient level cancer breast tumor protein breast cancer factor response concentration study plasminogen bcar 1 tamoxifen analysis status treatment activator therapy expression growth sepsis group bcar 1 levels vegf levels tamoxifen treatment growth factor table signi ficantly disease model survival value sample month receptor spermatozoa multivariate angiogenesi chemotherapy base model tissue adjuvant range result signi shock plasminogen activator system mutation outcome association correlation prognostic breast tumors inhibitor migration elisa netherland menopausal status mif levels 160 kda form pregnancy urokinase-type plasminogen activator radboud university nijmegen multivariate analysis macrophage migration relationship system fl uid death breast cancer patients tamoxifen therapy antibody oocyte kinase control women bcar 1 protein prognosis hormone
8 Most Recent Publications
|
Protein kinase Cδ expression in breast cancer as measured by real-time PCR, western blotting and ELISA
(Article)
McKiernan, E. O'Brien, K. Sweep, F.C. Duffy, M.J. Grebenchtchikov, N. Geurts-Moespot, A. Sieuwerts, A.M. Martens, J.W.M. Magdolen, V. Evoy, D. McDermott, E. Crown, J. |
2008-11-04
|
|
Complex congenital malformations and the impact of the plasminogen activator system and β-hCG in amniotic fluid
(Article)
Verkleij-Hagoort , A.C. Ursem, N.T.C. Hop, W.C.J. Geurts-Moespot, A. Steegers-Theunissen, R.P.M. Sweep, F.C. Steegers-Theunissen, R.P.M. |
2007-11-01
|
|
Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis
(Article)
Emonts, M. Sweep, F.C. Calandra, T. Grebenchtchikov, N. Geurts-Moespot, A. Knaup, M. Chanson, A.L. Erard, V. Renner, P. Hermans, P.W.M. Hazelzet, J.A. |
2007-05-15
|
|
Possible role of the plasminogen activation system in human subfertility
(Article)
Elbisch, I.M.W. Steegers-Theunissen, R.P.M. Sweep, F.C. Zielhuis, G.A. Geurts-Moespot, A. Thomas, C.M.G. |
2007-03-01
|
|
The prognostic value of BCAR1 in patients with primary breast cancer.
(Article)
Dorssers, L.C.J. Grebenchtchikov, N. Tienoven, D.T. van Geurts-Moespot, A. Span, P.N. Foekens, J.A. Sweep, F.C. Brinkman, A. Look, M.P. Broekhoven, S.P. van Jong, D. de Peters, H.A. Portengen, H. Meijer van Gelder, M.E. Klijn, J.G.M. |
2004-09-15
|
|
Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer.
(Article)
Dorssers, L.C.J. Grebenchtchikov, N. Brinkman, A. Look, M.P. Klijn, J.G.M. Geurts-Moespot, A. Span, P.N. Foekens, J.A. Sweep, C.G. |
2004-08-01
|
|
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer
(Article)
Berns, P.M.J.J. Portengen, H. Vossen, R. Peters, H. Geurts-Moespot, A. Staveren, I.L. van Foekens, J.A. Meijer van Gelder, M.E. Sweep, F.C. Bakker, B. Klijn, J.G.M. Look, M.P. Grebenchtchikov, N. |
2003-01-01
|
|
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer
(Article)
Foekens, J.A. Peters, H.A. Grebenchtchikov, N. Look, M.P. Meijer van Gelder, M.E. Geurts-Moespot, A. Kwast, Th.H. van der Sweep, C.G. Klijn, J.G.M. |
2001-01-01
|
